Business
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential
About this update from Erasca, Inc.
[{"type":"text","content":"Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30, 2025, in Chicago, Illinois. The abstracts will be available on the AACR 2025 meeting website. The posters will be available online at Erasca.com/science/presentations following the presentations. Poster Presentation Details Abstract 390 – ERAS-0015 is a pan-RAS molecular glue with best-in-class potential in RAS mutant solid tumorsDate/Time: Sunday, April 27, 2025, 2 – 5 PM CDT Session: Experimental and Molecular Therapeutics – Degraders and Glues 1Location: McCormick Place Convention Center, Poster Section 18, Poster Board 9 Abstract 4367 – ERAS-4001 is a pan-KRAS inhibitor with robust anti-tumor activity in KRAS altered solid tumorsDate/Time: Tuesday, April 29, 2025, 9 AM – 12 PM CDT Session: Experimental and Molecular Therapeutics – RAS InhibitorsLocation: McCormick Place Convention Center, Poster Section 21, Poster Board 2 Abstract 3152 – Identification and characterization of inhibitors SHOC2-MRAS-PP1C complex assemblyDate/Time: Monday, April 28, 2025, 2 – 5 PM CDTSession: Chemistry – High-Throughput Screening Assays and LibrariesLocation: McCormick Place Convention Center, Poster Section 25, Poster Board 5 About ErascaAt Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of patients with cancer. We have assembled one of the deepest RAS/MAPK pathway-focused pipe...